Glaxo opens broad expanded access program for abacavir (Ziagen).
Baker
R
R
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000600:supply & distribution* / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D015658:HIV Infections / Q000188:drug therapy*; D006297:Health Services Accessibility; D006801:Humans; D014481:United States; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D015507:Drugs, Investigational; D000099227:Abacavir